Buy Bristol-Myers Squibb

Logo for stock BMY (Bristol-Myers Squibb)

Amount

£
GBP

Latest price

$50.06
(£1.00 = $1.329)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$101.876B

P/E ratio

18.70

EPS

$2.677

Beta

0.41

Dividend rate

$2.44

Dividend yield

4.87%

About

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

CEO

Dr. Christopher S. (Chris) Boerner, Ph.D.

Employees

34,100

Sector

Health

Company HQ

PRINCETON, United States of America

Website

News

Logo for news article #0 (Bristol Myers to invest $40 billion in the US over 5 years, CEO says)

Bristol Myers to invest $40 billion in the US over 5 years, CEO says

Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday.

Reuters

May 05, 2025

Logo for news article #1 (First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now)

First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now

The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years.

24/7 Wall Street

May 01, 2025

Logo for news article #2 (This High-Yield Pharma Stock Looks Like an Incredible Bargain)

This High-Yield Pharma Stock Looks Like an Incredible Bargain

When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.

The Motley Fool

April 30, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.